Allogene Therapeutics (ALLO) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 18, 2026, with virtual participation and voting options for shareholders.

• Key 2025 milestones include progress in pivotal clinical trials, regulatory clearances, and operational realignment.

• Five proposals up for vote: director elections, executive compensation, say-on-pay frequency, share authorization increase, and auditor ratification.

• Forward-looking statements address clinical development, commercialization plans, and strategic initiatives.

Voting matters and shareholder proposals

• Election of three directors to serve until 2029.

• Advisory approval of executive compensation and preferred frequency of say-on-pay votes (Board recommends annual vote).

• Amendment to increase authorized common stock from 400M to 800M shares.

• Ratification of Ernst & Young LLP as independent auditor for 2026.

Board of directors and corporate governance

• Board reduced from 11 to 10 members, with a classified structure and annual self-evaluation.

• Majority of directors are independent; Lead Independent Director provides oversight.

• Board committees include Audit, Compensation, Nominating & Governance, International & Business Development, and R&D.

• Executive Chair compensated via consulting agreement reflecting expanded operational role.

• Board maintains robust stockholder engagement and transparent communication.